With the current increase of clinical trials in this area, most of them have not been included in a systematic evaluation to accurately compare the safety and efficacy of PD-L1 inhibitors as a second- or later-line therapy with those of chemotherapy for advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.